Keith Michael Gottesdiener - 08 May 2025 Form 4 Insider Report for Prime Medicine, Inc. (PRME)

Reporting relationship: Exhibit 24 - Power of Attorney; Title: President and Chief Executive Officer, Director
Issuer ticker: PRME
Reported as of: 08 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 May 2025, 16:50:03 UTC
Prior SEC filing: 04 Mar 2025
Next SEC filing: 29 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/ Ryan Brown, attorney-in-fact

Key filing fact

Keith Michael Gottesdiener filed Form 4 for Prime Medicine, Inc. (PRME) on 12 May 2025.

Key facts

This page summarizes Keith Michael Gottesdiener's Form 4 filing for Prime Medicine, Inc. (PRME).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 May 2025, 16:50.

Change

Previous filing in this sequence was filed on 04 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001615856 Primary reporting owner

Gottesdiener Keith Michael

Relationship: Exhibit 24 - Power of Attorney; Title: President and Chief Executive Officer, Director
Address: C/O PRIME MEDICINE, INC., 60 FIRST STREET, CAMBRIDGE
Signature: /s/ Ryan Brown, attorney-in-fact
Signature date: 12 May 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PRME transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +100,000
Change %: +50%
Price: $0.000000
Shares after: 300,000
Date: 08 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $8.32
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents an option initially granted to the Reporting Person on February 25, 2024, a portion of which shares underlying this option shall vest upon the achievement of certain performance milestones. On May 8, 2025, the board of directors of the Issuer determined that one of the performance milestone conditions was achieved, resulting in the vesting of 100,000 shares.

SEC remarks

Exhibit 24 - Power of Attorney; Title: President and Chief Executive Officer